The Importance of Self-Advocacy by Mara Klecker Donna Altes was in her late 70s when she received her melanoma diagnosis, which came after a…
Webinar: Post-ASCO Melanoma Research Update Each year, the American Society of Clinical Oncology (ASCO) Annual Meeting brings together leading cancer researchers and physicians from around…
Melanoma Monday: Every Day. Everywhere. May is Melanoma Awareness Month—but melanoma doesn’t follow a calendar. It doesn’t wait for summer vacations or long afternoons at…
Lilly Pulitzer and AIM at Melanoma Partner for 5th Annual Community Giving Event AIM at Melanoma is proud to partner once again with Lilly Pulitzer for their annual Community Giving Event. Now in…
KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as…
FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients On April 10, 2026, the U.S. Food and Drug Administration (FDA) issued a decision not to approve the resubmission of…
2026 National Sunscreen Partner We are proud to share that burnd Sunscreen has joined AIM at Melanoma as our 2026 National Sunscreen Partner. This…
Young Adult Cancer & Mental Health In this episode of Beyond the Clinic: Living Well with Melanoma, host Dr. Samantha Siegel sits down with Dr. Victoria…
Uveal Melanoma Webinar: Part II — Navigating Treatment in the Metastatic Setting Presented in partnership with Save Your Skin Foundation and Ocumel CanadaOcumel Canada (OC), is powered by Save Your Skin Foundation,…
Wade Watson, Stage III Melanoma Survivor A Diagnosis That Changed Everything In early 2021, Wade Watson and his father received life-changing news just weeks apart. His…
Jun. 23, 2026 Insights from the 2026 the American Academy of Dermatology (AAD) Annual Practice Safe Sun Survey
Jun. 09, 2026 The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public
Jun. 05, 2026 Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective